Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/15—Vitamins
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/16—Inorganic salts, minerals or trace elements
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
  • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

• the present invention relates to an alimentary integrator which results particularly useful in degenerative forms, in weakening of the immune system and in stepped-up organic deterioration.
• NA + - K + pump in the presence of oxidizing stress, does not perform its task correctly and there occurs an imbalance of the four fundamental cations which are needed to maintain cellular functioning, namely sodium, potassium, calcium and magnesium.
• Sodium NA + a prevalent cation in extracellular fluids
• Potassium K + tends to substitute Potassium K + inside the cell with a resulting serious imbalance and alteration of the NA - K pump.
• Aim of the present invention is to eliminate the above mentioned drawbacks providing with an alimentary integrator having the characteristics of claim 1.
• Other characteristics are object of the dipendent claims.
• the integrator is a very powerful anti-oxidizing that reduces the effect of free radicals; that it strengthens the activity of the immune system mantaining or revitalizing the concentration of intracellular potassium to the required levels; that it ties together the functional characteristics of its components giving rise to results surprisingly better in respect to the components sigularly used; that it is completely atoxyic (at prescribed doses); that it can be used over a long period of time; that it have a very simple posology.
• the alimentary integrator of the invention is constitued by a compound of Potassium Bicarbonate (KHCO 3 ) and an anti-oxidant agent that comprises D Ribose (C 5 H 10 O 5 ) and that can comprise Ascorbic Acid L (C 6 H 8 O 6 ).
• the integrator is constitued by a salt derived from Ascorbic Acid L, and is obtained by uniting Potassium Bicarbonate, Ascorbic Acid L and D Ribose in the purest crystallized form.
• the compound thus obtained, soluble in water, takes the name of Potassium Ribose Ascorbate.
• Ascorbic Acid salifies easily with alkaline bicarbonates dissolved in cold distilled water and with warm earthy-alkaline carbonates at a temperature of 45 - 50 °C, and working out of CO 2 . By cold evaporation, under high vacuum, crystallized salts (ascorbates) are obtained.
• Potassium Ribose Ascorbate is a pure microcrystalline easily water-soluble white salt and somewhat unstable due to its easy oxidizability. It is secured through the salification of Ascorbic Acid L and D Ribose in cold water solution with Potassium Bicarbonate. Its action does not produce any toxicity (given the stated dosages) and can be used for a long time. Biologically it follows the pattern of Ascorbic Acid.
• Potassium Ribose Ascorbate as an Ascorbic Acid derivate, it can take on two isomeric configurations: the oenolic form and the furanoid form; when in solution it assumes the latter form.
• Potassium Ribose Ascorbate that, as expressed above, is a very powerful anti-oxidizing, completely atoxyic that can be used over a long period of time (at prescribed doses), acts in a way that reduces the effect of free radicals, strengthening the activity of the immune system and maintaining or revitalizing the concentration of intracellular potassium to the required levels. It is therefore a most valid alimentary integrator and a very powerful cellular anti-oxidizer which ties together the functional characteristics of Ascorbic Acid L and of Potassium, manifesting itself as more active than the two constituents separatety taken. Moreover, the presence of D Ribose, for its charecteristics of a molecule structurally present in the intimate architecture of the cell, makes the compound more effective.
• Blood haemoglobin contains pyrrolic rings in its molecule; equally pyrrole derivates must be considered many fundamental amino acids. Also of note is the fact that black pigments, skin, hair, moles or birth-marks, etc are closely related to pyrrole black spots, which allows the assumption that said pigments are oxidized compounds and polycondensed compounds having a pyrrolic structure.
• Pyrrole, Thiophene and Furan are similar to each other; in the formation of their compounds they follow Angeli's rule of analogies. It is therefore reasonable to assume that during the biological synthesis process of protein derivatives from such compounds there may occur analogous chemical and physiological reactions and that under particular conditions a pyrrolic group may be replaced by a similar thiophenic or furanoid group.
• Both potassium haemoglobinate and potassium proteinate contain pyrrolic structures which can be salified with KHCO 3 ; the Potassium Ribose Ascorbate contains in its molecule a furanosic group which by analogy may replace one of the pyrrolic groups of potassium haemoglobinate and proteinate.
• Potassium Ribose Ascorbate in reactivating the pyrrolic group, restores the structuring phenomena of the cellular auto-synthesis to the required physiological normality.
• Potassium Ribose Ascorbate carried by haemoglobin and introduced into the cell, re-establishes the equilibrium amongst the intermolecular forces of the peptide groups which are present inside the cell membrane and brings back (or maintains) the required levels of the intracellular potassium concentration.
• Ascorbate Acid L residing in Potassium Ribose Ascorbate is fully capable of carrying out its functions, protecting above all the cell from the effects of free radicals, precisely by virtue of its anti-oxidizing characteristics, while D Ribose, as previously pointed out, amplifies the effect of the compound.
• Potassium Ribose Ascorbate is especially active against degenerative disease since, as explained earlier, when confronted by a degenerative process, it corrects the process of cellular metabolism by inhibiting its progress and giving it back the equilibrium of its functions with satisfactory results.
• the Potassium Ribose Ascorbate must be protected from humidity and the sun's rays and preserved separately in bags, phials or other suitable containers for preparing an extemporary solution of very pure Ascorbic Acid L, D Ribose and Bicarbonate of Potassium according to the proportions deriving from the experimental tests and of which is described an example.
• Each extemporary preparation comprises a bag or a phial of Ascorbic Acid L containing a dose of same, a bag or a phial of Potassium Bicarbonate containing two doses of same and a bag or a phial of D Ribose containing an amount between 0.1% and 10%, preferably 2%, of the inclusive dosage of Potassium Ascorbate.
• the contents are crystallized, in the phial the contents are in solution of bidistilled water.
• Potassium Ribose Ascorbate can be used at the same dosages of therapy but is can be administered only once a day, on alternate days.
• the preventive administration changes with the age.
• the compound of the present invention is a salt derived from D Ribose and it is obtained by uniting Potassium Bicarbonate and D Ribose in the purest crystallized form.
• the compound thus obtained, soluble in water, takes the name of Potassium Ribosate.
• Ascorbic Acid L and D Ribose are molecules of similar structure, and belong with the same functional group in which the hdyroxil O - H in the reaction affected in the Potassium Ribose Ascorbate formation is substituted by the O - K group.
• D Ribose is a fundamental substitute, with similar functional characteristics.
• Ribose salifies easily with alkaline bicarbonates dissolved in cold distilled water and with warm earthy-alkaline carbonates at a temperature of 45 - 50 °C, and working out of CO 2 , for its structural and functional characteristics similar to Ascorbic Acid L. By cold evaporation, under high vacuum, crystallized salts (ribosates) are obtained.
• Potassium Ribosate is a pure microcrystalline easily water-soluble white salt and somewhat unstable due to its easy oxidizability. It is secured through the salification of D Ribose in cold water solution with Potassium bicarbonate. Its action does not produce any toxicity (given the stated dosages) and can be used for a long time. Biologically it follows the pattern of Ascorbic Acid.
• Potassium Ribosate as an Ascorbic Acid precursor, it can take on two isomeric configurations: the oenolic form and the furanoid form; when in solution it assumes the latter form.
• Potassium Ribosate similarly to Potassium Ribose Ascorbate, is a very powerful anti-oxidizing, completely atoxyic that can be used over a long period of time (at prescribed doses), acts in a way that reduces the effect of free radicals, strengthening the activity of the immune system and maintaining or revitalizing the concentration of intracellular potassium to the required levels. It is therefore a most valid alimentary integrator and a very powerful cellular anti-oxidizer which ties together the functional characteristics of D Ribose and of Potassium, manifesting itself as more active than the two constituents separatety taken.
• Pyrrole, Thiophene and Furan are similar to each other; in the formation of their compounds they follow Angeli's rule of analogies. It is therefore reasonable to assume that during the biological synthesis process of protein derivatives from such compounds there may occur analogous chemical and physiological reactions and that under particular conditions a pyrrolic group may be replaced by a similar thiophenic or furanoid group.
• Both potassium haemoglobinate and potassium proteinate contain pyrrolic structures which can be salified with KHCO 3 ; the Potassium Ribose Ascorbate contains in its molecule a furanosic group which by analogy may replace one of the pyrrolic groups of potassium haemoglobinate and proteinate.
• Potassium Ribosate in reactivating the pyrrolic group, restores the structuring phenomena of the cellular auto-synthesis to the required physiological normality.
• Potassium Ribosate carried by haemoglobin and introduced into the cell, re-establishes the equilibrium amongst the intermolecular forces of the peptide groups which are present inside the cell membrane and brings back (or maintains) the required levels of the intracellular potassium concentration.
• the compound Potassium Ribosate protects the cell from the effects of free radicals, precisely by virtue of its anti-oxidizing characteristics.
• Potassium Ribosate is especially active against degenerative disease since, as explained earlier, when confronted by a degenerative process, it corrects the process of cellular metabolism by inhibiting its progress and giving it back the equilibrium of its functions with satisfactory results.
• the compund of Potassium Ribosate must be protected from humidity and the sun's rays and preserved separately in bags, phials or other suitable containers for preparing an extemporary solution of very pure Ascorbic Acid L, D Ribose and Bicarbonate of Potassium according to the following preferable proportions.
• the proportions provide to use a bag or a phial of Potassium bicarbonate containing two doses of same and a bag or a phial of D Ribose containing a dose of same. It is possible to use three doses of Potassium Bicarbonate and a dose of D Ribose.
• the contents of a dose of Ribose and two doses of Potassium bicarbonate can be blended in order to obtain the cold extemporary solution of Potassium Ribosate to be admistered, for example, three times a day.
• Potassium Ribosate Ascorbate the above described general course of action of Potassium Ribosate may undergo variations due to particular physiopathological conditions, according to medical evaluation, for instance, by doubling the Potassium bicarbonate dosage (determining a 4-1 relation between Potassium Bicarbonate and D Ribose) or by reducing the daily administration of the medication; at any rate, the maximum dosage of Potassium Ribosate should not exceed 2 g daily.
• Potassium Ribosate can be used similarly to Potassium Ribose Ascorbate.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Mycology (AREA)
• Inorganic Chemistry (AREA)
• Polymers & Plastics (AREA)
• Food Science & Technology (AREA)
• Engineering & Computer Science (AREA)
• Nutrition Science (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Medicinal Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)
• Medicines Containing Plant Substances (AREA)

Applications Claiming Priority (2)

Publications (2)

Family

ID=19740572

Family Applications (1)

Country Status (4)

Cited By (3)

Citations (4)

• 1999
  • 1999-03-19 DE DE69914395T patent/DE69914395T2/de not_active Expired - Lifetime
  • 1999-03-19 EP EP99830153A patent/EP0945075B1/fr not_active Expired - Lifetime
  • 1999-03-19 AT AT99830153T patent/ATE258387T1/de not_active IP Right Cessation
  • 1999-03-19 ES ES99830153T patent/ES2214003T3/es not_active Expired - Lifetime

Patent Citations (4)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events